Innovent Biologics Inc. has announced that its self-developed recombinant anti-interleukin-23p19 subunit monoclonal antibody, PECONDLE® (picankibart injection), met both primary and key secondary efficacy endpoints in the Phase 3 CLEAR-2 study. The CLEAR-2 trial was a randomized withdrawal and retreatment study conducted in Chinese participants with moderate-to-severe plaque psoriasis. PECONDLE® received market approval from the National Medical Products Administration (NMPA) in November 2025 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The results of the Phase 3 study have already been announced.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN41267) on December 09, 2025, and is solely responsible for the information contained therein.